Nivolumab Plus Relatlimab Fails to Improve RFS in Resected Stage III/IV Melanoma
Source: OncLive, January 2025
Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.
Adjuvant treatment with nivolumab and relatlimab-rmbw (Opdualag) did not improve recurrence-free survival (RFS) compared with nivolumab (Opdivo) monotherapy in patients with completely resected stage III/IV melanoma, missing the primary end point of the phase 3 RELATIVITY-098 trial (NCT05002569).
In a news release, Bristol Myers Squibb noted that the safety profile of nivolumab and relatlimab was consistent with previously reported safety data.